Immunohistochemical expression of p21 in normal tissues of salivary gland, pleomorphic adenoma and carcinoma ex pleomorphic adenoma-(undifferentiated and adenocarcinoma types)

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 15, Issue 5, 2010, Pages

  Tarakji, Bassel ^a   Nassani, Mohammad Z ^a  

^a UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

Author keywords

Carcinoma ex pleomorphic adenoma; p21 expression; Pleomorphic salivary adenoma

Indexed keywords

PROTEIN P21;

ACINAR CELL; ADENOCARCINOMA; ADULT; AGED; ARTICLE; CARCINOMA CELL; CARCINOMA EX PLEOMORPHIC ADENOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND; PLEOMORPHIC ADENOMA; PROTEIN EXPRESSION; SALIVARY GLAND; SUBMANDIBULAR GLAND; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADENOMA, PLEOMORPHIC; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; YOUNG ADULT;

EID: 77956418180     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.15.e697     Document Type: Article

References (16)

1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.
2. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-74.
3. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36:3-7.
4. Horn-Ross PL, West DW, Brown SR. Recent trends in the incidence of salivary gland cancer. Int J Epidemiol. 1991;20:628-33.
5. Olsen KD, Lewis JE. Carcinoma ex pleomorphic adenoma: a clinicopathologic review. Head Neck. 2001;23:705-12.
6. Eneroth CM, Zetterberg A. Malignancy in pleomorphic adenoma. A clinical and microspectrophotometric study. Acta Otolaryngol. 1974;77:426-32.
7. Gnepp DR. Malignant mixed tumors of the salivary glands: a review. Pathol Annu. 1993;28 Pt 1:279-328.
8. Nagao K, Matsuzaki O, Saiga H, Sugano I, Shigematsu H, Kaneko T, et al. Histopathologic studies on carcinoma in pleomorphic adenoma of the parotid gland. Cancer. 1981;48:113-21. (Pubitemid 11064387)
9. Rey MJ, Fernández PL, Jares P, Muñoz M, Nadal A, Peiró N, et al. P21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998;184:265-71.
10. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Dräger BJ. Frequent and heterogeneous expression of cyclin- dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer. 1998;77:515-21. (Pubitemid 28059455)
11. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995;11:2021-8.
12. Zhu Q, Tipoe GL, White FH. Proliferative activity as detected by immunostaining with Ki-67 and proliferating cell nuclear antigen in benign and malignant epithelial lesions of the human parotid gland. Anal Quant Cytol Histol. 1999;21:336-42.
13. De Lima Mde D, Marques YM, Alves Sde M Jr, Freitas VM, Soares FA, de Araújo VC, et al. MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009;33:142-6.
14. Marques YM, de Lima Mde D, de Melo Alves Sde M Jr, Soares FA, de Araújo VC, Pinto Ddos S Jr, et al. Mdm2, p53, p21 and pAKT protein pathways in benign neoplasms of the salivary gland. Oral Oncol. 2008;44:903-8.
15. Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;75:1617-20.
16. Brunotto M, Zárate AM, Cismondi A, Fernández Mdel C, Noher de Halac RI. Valuation of exfoliative cytology as prediction factor in oral mucosa lesions. Med Oral Patol Oral Cir Bucal. 2005;10 Suppl 2:E92-102.